The global bone growth stimulators market was worth around USD 1.21 billion in 2021 and is estimated to grow to about USD 1.85 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.2 percent over the forecast period.
The global bone growth stimulators market was worth around USD 1.21 billion in 2021 and is estimated to grow to about USD 1.85 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.2 percent over the forecast period. The report analyzes the bone growth stimulators market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the bone growth stimulators market.
Bone growth stimulation promotes bone healing in difficult-to-heal fractures or fusions by administering an ultrasonic or electrical current to the fracture site. This is done by an electrical osteogenesis stimulator, it’s a device that stimulates bone regeneration via electrical stimulation. Electrical stimulation can be administered from the outside (noninvasive) or the interior of the body (invasive). An external power supply is connected to electrodes or coil implanted on the skin or plaster or brace over a fusion or fracture site in a noninvasive electrical stimulator. A noninvasive device that generates low intensity, pulsed ultrasound is known as an ultrasonic osteogenesis stimulator. In order to encourage fracture healing, an ultrasonic signal is given to the skin surface at the fracture region through ultrasound conductive coupling gel.
The COVID-19 pandemic is likely to have an interim negative impact on the global bone growth stimulators market. This is due to a sudden drop in elective surgeries, ban on organized sports, the momentary shutdown of O&P health centers, restricted access to non-essential care, and slowed in-patient flow & referrals. However, crucial European and Chinese markets are showing indications of revival. The market is expected to gradually rise in late in the second half of 2022, which could be attributed to handling pre-COVID elective surgeries, an increasing number of surgeries as a result of clearing backlogs & new cases, completely revived healthcare services, large-scale recreation & physical work, and the restarting of organized sports.
Increase patient preference towards minimally invasive and non-invasive surgical operations.
Because of the benefits offered by non-invasive and minimally invasive treatments over standard treatment techniques, there has been a huge growth in demand for them. Less operating problems, nominal hospitalization, smaller aesthetic incisions, less discomfort, minimal risk of infection, shortened postoperative care, and quicker recovery are all advantages of minimally invasive treatments. In minimally invasive treatments, advanced technology is used to detect and treat several disorders, including cancer. These treatments are intended to remove malignant tumors and lymph nodes from the body without leaving scars. These factors are contributing to the market growth.
Limitations for medical reimbursement for bone stimulating procedures may hinder the market growth.
At a country level, medical reimbursement is one of the most important variables influencing the acceptance and demand of certain diagnostic or therapeutic goods among patients and healthcare professionals. In developed nations (such as the United States and Australia), the majority of healthcare insurance companies cover bone growth stimulation drugs provided certain requirements are met. In the United States, for example, insurance provided for bone growth stimulation devices providing the target bones are apart by less than one centimeter and are not diseased. According to the Part B schedule, Medicare also covers bone growth stimulating devices and provides device rental on a prescription basis but for various purposes. Moreover, many private insurance companies, on the other hand, do not cover or reimburse bone growth stimulating operations, thereby by hindering market growth to some extent.
Increasing demand for bone growth stimulators in emerging countries will provide better growth opportunities to the market.
Emerging economies like India, China, Mexico, and Brazil are likely to offer considerable growth potential for the bone growth stimulators market. Factors such as a large population of patients, soaring healthcare spending, increasing government support for the healthcare industry, bolstering export trade, and increasing awareness among surgeons, physicians, and patients regarding the latest treatment options for spinal fusion and bone therapies are estimated to bolster the requirement for bone growth stimulation devices. Furthermore, many patients from established countries are known to fly to these emerging nations for medical care because of the huge cost savings.
Side-effects of BMP-based orthopedic therapy pose a major challenge to expanding the market growth.
Even though BMPs are increasingly being employed in bone healing and spinal fusion, they are linked to several negative side effects. The most common adverse effects of BMPs following spinal fusion surgery include tissue edema, implant dislodgement, and male infertility. BMPs have been linked to antigenic responses and oncogene activation during bone repair. During the use of Medtronic's BMP product in spinal fusion procedures for bone repair, the company identified various clinical problems.
The global bone growth stimulators market is categorized into product, application, distribution channel, and region. Based on the product, the market is bifurcated into bone morphogenetic proteins, bone growth stimulation devices, and platelet-rich plasma. The application segment of the market is segregated as spinal fusion surgeries, oral & maxillofacial surgeries, delayed union & nonunion bone fractures, and others. The distribution channel segment is split into home care, hospitals & clinics, and others.
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2022 |
Historic Years | 2018 - 2022 |
Forecast Years | 2023 - 2030 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2023 to 2030 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
North America to remain the largest market for bone growth stimulators over the forecast period.
North America has the highest share of the global bone growth stimulators market. North America's significant market share is owing to a well-developed healthcare structure and medical reimbursement system in the United States and Canada. Along with that, increased physician and patient knowledge of novel treatment techniques and technologies in the United States and Canada is also supporting the regional market growth. Furthermore, the increasing incidences of spinal disorders, increasing geriatric population, higher population health risk due to smoking, obesity, & diabetes are also supporting the market growth. Additionally, increasing patient preference for non-invasive orthopedic treatments is fueling the market growth for bone growth stimulators in North America.
Key players in the global bone growth stimulators market include Orthofix Medical, Inc., Zimmer Biomet, DJO Finance, LLC, Stryker, Bioventus LLC, Medtronic plc, Arthrex, Inc., DePuy Synthes, Isto Biologics, Ember Therapeutics, Inc., Terumo Corporation, Altis Biologics (Pty) Ltd., Ossatec Benelux Ltd., Regen Lab SA, Elizur Corporation, ITO Co., Ltd., and BTT Health GmbH.
By Product
By Application
By Distribution Channel
By Region
FrequentlyAsked Questions
High demand for minimally invasive treatments booting the market growth. Because of the benefits offered by non-invasive and minimally invasive treatments over standard treatment techniques, there has been a huge growth in demand for them. Less operating problems, nominal hospitalization, smaller aesthetic incisions, less discomfort, minimal risk of infection, shortened postoperative care, and quicker recovery are all advantages of minimally invasive treatments. In minimally invasive treatments advanced technology is used to detect and treat a several disorders, including cancer. These treatments are intended to remove malignant tumors and lymph nodes from the body without leaving scars. These factors are contributing to the market growth.
According to the Zion Market Research report, the global bone growth stimulators market was worth about 1.21 (USD billion) in 2021 and is predicted to grow to around 1.85 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 5.2 percent.
North America has the highest share of the bone growth stimulators market. North America's significant market share is owing to well-developed healthcare structure and medical reimbursement system in the United States and Canada. Along with that, increased physician and patient knowledge of novel treatment techniques and technologies in the United States and Canada is also supporting the regional market growth. Furthermore, the increasing incidences of spinal disorders, increasing geriatric population, higher population health risk due to smoking, obesity, and diabetes are also supporting the market growth.
Key players in the global bone growth stimulator market include Orthofix Medical, Inc., Zimmer Biomet, DJO Finance, LLC, Stryker, Bioventus LLC, Medtronic plc, Arthrex, Inc., DePuy Synthes, Isto Biologics, Ember Therapeutics, Inc., Terumo Corporation, Altis Biologics (Pty) Ltd., Ossatec Benelux Ltd., Regen Lab SA, Elizur Corporation, ITO Co., Ltd., and BTT Health GmbH.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed